Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Cerebral invasive aspergillosis in a case of chronic lymphocytic leukemia with bruton tyrosine kinase inhibitorCurrent Oncology.  28:837-841. 2021
2021 Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202) 2021
2020 A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaBlood.  136:2401-2409. 2020
2020 Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study 2020
2020 Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines 2020
2020 Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies a CClinical Cancer Research.  26:1247-1257. 2020
2020 Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogeneticsBlood Advances.  4:253-262. 2020
2020 Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphomaAmerican Journal of Hematology.  95:18-27. 2020
2019 A review of chimeric antigen receptor T-cells in lymphomaExpert Review of Hematology.  12:551-561. 2019
2019 Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study 2019
2019 The impact of structural factors on diagnostic delay in diffuse large B-cell lymphomaCancer Medicine.  8:1416-1422. 2019
2019 AIDS-related Kaposi sarcoma, version 2.2019 2019
2019 B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines 2019
2019 Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab eraJournal of Clinical Oncology.  37:471-480. 2019
2018 Primary Bone Marrow Diffuse Large B-cell Lymphoma Presenting as Transverse MyelitisAmerican Journal of the Medical Sciences.  356:561-566. 2018
2018 Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsNature Communications.  9. 2018
2018 Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based studyCancer.  124:4221-4230. 2018
2018 Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic TargetsEuropean urology focus.  4:733-736. 2018
2018 Cancer in people living with HIV, version 1.2018: Clinical practice guidelines in oncology 2018
2018 Imitating the great imitator: The intersection of sarcoidosis and hodgkin’s lymphoma a report of two cases 2018
2018 Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary educationTranslational Behavioral Medicine.  8:175-182. 2018
2018 T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines 2018
2017 C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapyCancer.  123:4411-4418. 2017
2017 PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHDBlood.  130:221-228. 2017
2017 Treatment approaches of hard-to-treat non-Hodgkin lymphomasExpert Review of Hematology.  10:259-273. 2017
2017 Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesAmerican Journal of Hematology.  92:161-170. 2017
2017 Diagnostic, prognostic and therapeutic role of CD30 in lymphomaExpert Review of Hematology.  10:29-37. 2017
2017 Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targetsOncotarget.  8:21710-21718. 2017
2017 Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinomaOncotarget.  8:29220-29232. 2017
2016 Amitkumar Mehta on the Immunomodulating Effects of Targeted Therapy for Multiple Myeloma 2016
2016 Amitkumar Mehta on the immunomodulating effects of targeted therapy for multiple myeloma 2016
2016 Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapyExpert Review of Hematology.  9:471-477. 2016
2016 Treatment of CD30-positive systemic mastocytosis with brentuximab vedotinLeukemia Research.  44:25-31. 2016
2015 Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin LymphomaCurrent Oncology Reports.  17. 2015
2015 High throughput kinomic profiling of human clear cell renal cell carcinoma identifies kinase activity dependent molecular subtypesPLoS ONE.  10. 2015
2015 Advanced prostate cancer presenting as bilateral testicular hydroceleIndian Journal of Cancer.  52:264-265. 2015
2015 Tivozanib: Status of DevelopmentCurrent Oncology Reports.  17:1-7. 2015
2015 Current trends in the treatment of mantle cell lymphoma 2015
2015 Novel agents for the treatment of Hodgkin lymphomaExpert Review of Hematology.  8:659-667. 2015
2014 A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinomaBJU International.  113. 2014
2014 Disseminated fusariosis during acute myelogenous leukemia induction treatmentBlood.  123:3379. 2014
2014 How do i recommend extended adjuvant hormonal therapy?Current Treatment Options in Oncology.  15:55-62. 2014
2014 Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapyUrologic Oncology: Seminars and Original Investigations.  32:501-508. 2014
2014 Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaClinical Genitourinary Cancer.  12:130-137. 2014
2014 Tivozanib for the treatment of renal cell carcinoma: Results and implications of the TIVO-1 trialFuture Oncology.  10:1819-1826. 2014
2014 Update in systemic therapy of urologic malignanciesPostgraduate Medicine.  126:44-54. 2014
2013 Heparin induced thrombocytopenia: ReviewExpert Review of Hematology.  6:419-428. 2013
2013 A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCTBone Marrow Transplantation.  48:461-462. 2013
2013 Current advances in understanding and managing secondary brain metastasisCNS Oncology.  2:75-85. 2013
2011 Massive pulmonary embolism and cardio-pulmonary resuscitation leading to disseminated intravascular coagulationAsian Journal of Transfusion Science.  5:188-189. 2011
2011 An unusual case of squamous cell carcinoma of lung with metastases to the heartIndian Journal of Cancer.  48:266-267. 2011

Chapter

Year Title Altmetric
2015 Mantle cell lymphoma: Current treatment strategies in the era of targeted agents.  35-62. 2015

Principal Investigator On

  • UAB 2078: A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin  awarded by ARTIVA BIOTHERAPEUTICS INC 2021 - 2026
  • Private Grant  awarded by JUNO THERAPEUTICS 2021 - 2026
  • UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study  awarded by City of Hope 2021 - 2026
  • Private Grant  awarded by INCYTE CORPORATION 2020 - 2025
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by JUNO THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by TG THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by KITE PHARMA 2019 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2021 - 2024
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2019 - 2024
  • Private Grant  awarded by Genentech 2019 - 2024
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2020 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by PHARMACYCLICS, INC. 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2022
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2020 - 2022
  • Private Grant  awarded by AFFIMED GMBH 2020 - 2022
  • Private Grant  awarded by Genentech 2019 - 2022
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2022
  • Private Grant  awarded by FORTY SEVEN, INC. 2018 - 2022
  • Private Grant  awarded by INNATE PHARMA 2020 - 2022
  • Private Grant  awarded by EPIZYME - NEW 2016 - 2021
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2015 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2021
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2018 - 2021
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2021
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by ONCOTARTIS, INC. 2019 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2021
  • Private Grant  awarded by ADC THERAPEUTICS SA 2019 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2015 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2021
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2018 - 2020
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2020
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2020
  • Private Grant  awarded by Gilead Sciences ^ 2018 - 2020
  • Private Grant  awarded by MIRAGEN THERAPEUTICS INC. 2019 - 2020
  • Private Grant  awarded by Genentech 2018 - 2020
  • Outcomes of Limited Stage Diffuse Large B-Cell Lymphoma with MYC Rearrangement  awarded by Roswell Park Cancer Institute 2018 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2017 - 2019
  • Private Grant  awarded by IMMUNOGEN, INC. 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2017 - 2018
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by Genentech 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016
  • Private Grant  awarded by MedImmune 2014 - 2016
  • Investigator On

  • AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2020 - 2026
  • Private Grant  awarded by GENMAB 2021 - 2026
  • Private Grant  awarded by GENMAB 2021 - 2026
  • Private Grant  awarded by Genentech 2020 - 2025
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by TG THERAPEUTICS 2020 - 2024
  • Private Grant  awarded by SUTRO BIOPHARM 2020 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • Private Grant  awarded by CELGENE CORPORATION 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by Gilead Sciences ^ 2021 - 2024
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC. 2021 - 2024
  • Private Grant  awarded by AMGEN, INC.^ 2018 - 2023
  • Private Grant  awarded by TAKEDA PHARMACEUTICALS COMPANY LTD 2020 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2018 - 2023
  • Private Grant  awarded by IOVANCE BIOTHERAPEUTICS INC. 2018 - 2023
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2020 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by CELGENE INTERNATIONAL II SÀRL 2018 - 2023
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2019 - 2023
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED 2020 - 2023
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2021
  • Private Grant  awarded by MedImmune 2010 - 2020
  • Private Grant  awarded by AILERON THERAPEUTICS 2015 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by AFFIMED GMBH 2016 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2019
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC. 2015 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Private Grant  awarded by ROCHE TCRC, INC. 2018 - 2019
  • Private Grant  awarded by INCYTE CORPORATION 2018 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2018 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by MERCK & COMPANY, INC. ^ 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by Genentech 2015 - 2018
  • Private Grant  awarded by TESARO, INC. 2016 - 2018
  • Private Grant  awarded by Gilead Sciences ^ 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2018
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2018
  • Private Grant  awarded by FORTY SEVEN, INC. 2017 - 2018
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014 - 2018
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018
  • Private Grant  awarded by JUNO THERAPEUTICS 2016 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2016 - 2017
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2012 - 2017
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^ 2015 - 2017
  • Private Grant  awarded by GlaxoSmithKline 2013 - 2016
  • Private Grant  awarded by MedImmune 2012 - 2016
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2011 - 2015
  • Whole Exome and Comprehensive Kinomics Analysis of Penile Squamous Cell Carcinoma  awarded by Conquer Cancer Foundation of ASCO 2014 - 2015
  • Private Grant  awarded by AILERON THERAPEUTICS 2015
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), The Maharaja Sayajirao University of Baroda 2002
  • George Washington University Hospital, Residency 2011
  • UAB Hospital, Postdoctoral Fellowship 2014
  • Full Name

  • Amitkumar Mehta